CM
CMND.US Clearmind Medicine Inc. Common Shares
- Market cap
- USD 2.30M
- P/E
- -
- P/B
- 0.18x
- ROE
- -70.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jul 2026.
Is CMND.US undervalued?
Graham numberThe Graham number of Clearmind Medicine Inc. Common Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Clearmind Medicine Inc. Common Shares fundamental analysis
No fundamental analysis for Clearmind Medicine Inc. Common Shares yet.
Clearmind Medicine Inc. Common Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Clearmind Medicine Inc. Common Shares
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and me…
Full company profileClearmind Medicine Inc. Common Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Clearmind Medicine Inc. Common Shares annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | - | - | - | - | -2.53K | -120K | -57.4K | -51.1K | -49.4K | -55.2K |
| Operating Income | -24.2K | -6.53K | -255K | -105K | -233K | -3.61M | -9.00M | -6.29M | -5.74M | -5.67M | -9.88M |
| EBITDA | - | -6.53K | -255K | -105K | -233K | -3.65M | -9.75M | -8.53M | -4.79M | -3.72M | -10.1M |
| Net Income | -24.2K | -6.53K | -195K | -105K | -233K | -3.66M | -9.93M | -8.61M | -5.25M | -3.86M | -9.08M |
| EPS | - | -17 | -577 | -273 | -411 | -3,785 | -7,333 | -1,360 | -54 | -24 | -46 |
| Balance Sheet | |||||||||||
| Total Assets | 4.30K | 101K | 188K | 135K | 385K | 4.16M | 1.12M | 5.95M | 10.1M | 6.08M | 16.9M |
| Total Liabilities | 50.0K | 51.3K | 5.83K | 33.8K | 10.0K | 288K | 2.62M | 4.97M | 5.77M | 4.89M | 3.96M |
| Shareholders' Equity | -45.7K | 49.4K | 182K | 102K | 375K | 3.87M | -1.50M | 983K | 4.33M | 1.19M | 13.0M |
| Cash & Short-term Investments | 4.30K | 79.9K | 56.2K | 522.51 | 248K | 3.71M | 438K | 5.51M | 9.55M | 5.58M | 15.9M |
| Total Debt | - | - | - | - | - | - | 52.1K | - | 74.0K | 1.78M | 1.80M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -15.4K | -8.93K | -80.5K | -47.9K | -199K | -2.08M | -5.06M | -6.30M | -6.76M | -4.73M | -7.65M |
| Capital Expenditure | 0.00 | 18.4K | 100.0K | 7.59K | 7.51K | 169K | 7.55K | 0.00 | 0.00 | 0.00 | 5.33 |
| Free Cash Flow | - | -27.5K | -180K | -55.4K | -206K | -2.25M | -5.06M | -6.30M | -6.76M | -4.73M | -7.65M |
| Ratios | |||||||||||
| ROE | - | -13.2% | -106.7% | -103.6% | -62.2% | -94.4% | - | -875.4% | -121.5% | -323.4% | -70.1% |
| ROA | -563.3% | -6.5% | -103.4% | -77.7% | -60.6% | -87.8% | -885.1% | -144.6% | -52.0% | -63.4% | -53.7% |
| Debt to Equity | - | - | - | - | - | - | - | - | 0.02x | 1.49x | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Clearmind Medicine Inc. Common Shares dividends
Clearmind Medicine Inc. Common Shares has not paid dividends in the last 9 fiscal years.
Last stock split: 1:8 on Oct 5, 2026.
Who owns Clearmind Medicine Inc. Common Shares
- Insiders 5.02%
- Institutions 1.25%
- Public & others 93.73%
- Shares outstanding 507K
- Free float 394K
Top funds holding CMND.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AdvisorShares Psychedelics ETF | 1.44K | 0.04% | 0.00% | Sep 2026 |
Top institutions holding CMND.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 35.1K | 0.87% | +2,108.86% | Jun 2026 |
| Citadel Advisors Llc | 11.7K | 0.29% | 0.00% | Jun 2026 |
| AdvisorShares Investments, LLC | 1.17K | 0.03% | +58.83% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 700.00 | 0.02% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 287.00 | 0.01% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | 0.00% | Jun 2026 |
Clearmind Medicine Inc. Common Shares company profile
- Company name
- Clearmind Medicine Inc. Common Shares
- Ticker
- CMND.US
- ISIN
- CA1850536006
- Exchange
- USA Stocks
- Listed since
- Aug 16, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- October
- Address
- 1220 West 6th Avenue, Vancouver, BC, Canada, V6H 1A5
- Phone
- 973 536 1016
- Website
- clearmindmedicine.com
About Clearmind Medicine Inc. Common Shares
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Clearmind Medicine Inc. Common Shares management
6- Dr. Adi Zuloff-Shani Ph.D.Chief Executive Officer · born 1967
- Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPAChief Financial Officer · born 1952
- Prof. Mark Haden M.S.W.Vice President of Business Development · born 1953
- Ms. Mylene TouboulAccounting Manager
- Ms. Mary-Elizabeth GiffordChief of Global Impact
- Ms. Adi VaronController